Anvisa Approves Groundbreaking Oral Drug for Breast Cancer: Revolutionary Treatment for HER2-Positive Patients

Brazil’s National Health Surveillance Agency (Anvisa) has approved the first oral medication specifically for advanced breast cancer, marking a significant advancement in treatment options for patients with hormone receptor-positive (HR+) disease. The drug, ribociclib (brand name Kisqali), joins a growing class of targeted therapies that promise to improve survival rates and quality of life for thousands of women in Brazil.

Developed by pharmaceutical company Pfizer in collaboration with Novartis, ribociclib is a CDK4/6 inhibitor—a class of drugs that has revolutionized breast cancer care globally. Unlike traditional chemotherapy, which often requires intravenous infusion, this oral treatment allows patients to manage their condition with daily pills, reducing hospital visits and improving convenience. The approval comes as Brazil faces one of the highest breast cancer incidence rates in Latin America, with over 66,000 new cases diagnosed annually.

Anvisa’s decision follows rigorous clinical trials demonstrating the drug’s efficacy in extending progression-free survival—a critical metric for advanced breast cancer patients. According to the Monaleesa-7 trial, published in the New England Journal of Medicine, ribociclib reduced the risk of disease progression or death by 44% compared to placebo when combined with hormone therapy. The drug is now available for patients with HR+, HER2-negative advanced or metastatic breast cancer.

What Is Ribociclib and How Does It Work?

Ribociclib belongs to a class of medications called cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. These drugs work by blocking specific proteins that drive uncontrolled cell division in cancer cells. In breast cancer, this mechanism helps slow tumor growth while allowing hormone therapy (such as tamoxifen or aromatase inhibitors) to work more effectively.

Unlike older treatments that relied on broad-spectrum toxicity to kill cancer cells, CDK4/6 inhibitors offer a more targeted approach. “This precision medicine strategy not only improves outcomes but also reduces side effects for patients,” explains Dr. Ana Maria Menezes, a breast cancer specialist at the National Cancer Institute of Brazil (INCA). “For many women, the ability to take a pill at home rather than undergoing weekly infusions is a game-changer in terms of quality of life.”

The drug’s approval in Brazil follows its initial FDA approval in 2017 and subsequent authorization in over 100 countries. Pfizer has stated that it will work with Brazilian health authorities to ensure affordable access for patients, though pricing details have not yet been disclosed.

Who Benefits from This Approval?

The new treatment is specifically indicated for postmenopausal women with HR+, HER2-negative advanced or metastatic breast cancer. This subgroup represents approximately 70% of all breast cancer cases, making the approval particularly impactful. Key patient groups include:

• Newly diagnosed advanced breast cancer patients: Ribociclib, when combined with hormone therapy, can delay disease progression by months or even years.
• Patients who have progressed on previous endocrine therapy: Clinical trials show significant benefits for those whose cancer has returned after initial treatment.
• Elderly patients or those with comorbidities: The oral formulation reduces the need for frequent hospital visits, which is especially beneficial for older adults or those with limited mobility.

Dr. Menezes emphasizes that while ribociclib is not a cure, it represents a “meaningful step forward” in managing advanced breast cancer. “For many patients, this drug will buy them precious time—time to spend with family, pursue treatment options, or simply maintain their daily lives with less suffering,” she says.

How Does This Compare to Existing Treatments?

Brazil already had access to other CDK4/6 inhibitors, including palbociclib (Ibrance) and abemaciclib (Verzenio), both approved by Anvisa in recent years. However, ribociclib offers distinct advantages:

While all three drugs target the same pathway, ribociclib’s approval expands treatment options, allowing oncologists to tailor therapy based on individual patient profiles. “Having multiple CDK4/6 inhibitors available increases the likelihood that we can find the right match for each patient,” notes Dr. Carlos Eduardo Bacchi, president of the Brazilian Society of Clinical Oncology (SBOC).

What Are the Next Steps for Patients and Doctors?

Patients with advanced breast cancer should consult their oncologist to determine if ribociclib is an appropriate option. The drug will be prescribed under Anvisa’s special control system, meaning doctors must follow strict guidelines for administration and monitoring.

Key considerations for patients include:

• Eligibility: Confirmation of HR+, HER2-negative status through genetic testing.
• Combined therapy: Ribociclib must be used with an aromatase inhibitor or fulvestrant.
• Side effect management: Regular blood tests to monitor for neutropenia (low white blood cell count).
• Cost and insurance: Patients should check with their health insurer (SUS or private) about coverage. Pfizer has committed to patient assistance programs for those in need.

For healthcare providers, the approval introduces new protocols for monitoring and managing side effects. “We’ll need to educate patients about the importance of adherence and symptom reporting,” says Dr. Bacchi. “This drug works best when taken consistently, but it also requires proactive management of potential complications.”

What Happens Next in Brazil’s Breast Cancer Treatment Landscape?

Anvisa’s approval of ribociclib is part of a broader trend in Brazil toward adopting innovative cancer therapies. The agency has accelerated reviews for several oncology drugs in recent years, reflecting a commitment to improving patient access to cutting-edge treatments.

Looking ahead, experts anticipate:

• Expanded access programs: Pfizer and Novartis are likely to launch initiatives to support uninsured or underinsured patients.
• Clinical trial enrollment: New studies may explore ribociclib’s efficacy in earlier-stage breast cancer or combination therapies.
• Health policy discussions: The approval may prompt debates about SUS coverage for high-cost cancer drugs and how to balance innovation with affordability.

The next major checkpoint will be the publication of Anvisa’s full regulatory decision, which will include detailed prescribing information and safety monitoring requirements. Patients and providers are advised to monitor updates from Anvisa’s official communications and INCA.

For those affected by breast cancer, the approval offers renewed hope. As Dr. Fischer notes, “Advances like this remind us that while breast cancer remains a formidable challenge, science and regulatory progress are steadily improving the outlook for patients worldwide.”

Have you or a loved one been impacted by breast cancer? Share your experiences or questions in the comments below—or spread the word to someone who may benefit from this news.